How Peptide Synthesis Affects Purity and Safety

How Synthesis Quality Affects a Peptide

Two vials with the same label can hold quite different contents, and the difference usually comes down to how the peptide was made and purified. Many users assume a milligram of sermorelin is a milligram of sermorelin no matter where it comes from. Independent testing of gray-market vials, covered at the end of this page, suggests that assumption often doesn't hold.

Every synthetic peptide was built amino acid by amino acid in a lab. A well-made batch has the correct sequence and very little else in the vial. A poorly made one can contain failed sequences and leftover reagents, and some batches also carry bacterial endotoxin. Some of these impurities probably do nothing. Others may cause injection-site reactions or immune responses that are hard to tell apart from effects of the peptide itself.

Knowing how peptides are made helps explain why sourcing and testing matter, and why some of what users attribute to a peptide may come from something else in the vial. The rest of our monitoring and contraindications section covers the health side of that risk.

Building a Peptide: Solid-Phase Synthesis

GHRP-2, for example, is a specific sequence of six amino acids. Most peptides made today, research peptides included, are built by solid-phase peptide synthesis (SPPS). Bruce Merrifield developed the method in the early 1960s and won the 1984 Nobel Prize in Chemistry for it.

In SPPS, the first amino acid in the peptide chain is chemically anchored to an insoluble polymer bead, the "solid phase." From there, the lab adds the next amino acid in the sequence, runs a chemical reaction to bind it to the first, and then washes away all the excess reagents. The lab repeats this cycle (add, bind, wash) for every amino acid in the chain. For a short peptide like ipamorelin (5 amino acids), this cycle runs 4 times. For sermorelin (29 amino acids), it runs 28 times.

Once the full chain is built, a final chemical reaction (usually with an acid like trifluoroacetic acid, or TFA) cleaves the completed peptide off the resin bead. What's left is a raw, unpurified peptide mixture, and this is where most quality problems begin.

Impurities From Synthesis

That raw mixture is far from clean. The SPPS process, even when done well, is not 100% efficient. Each cycle has a small failure rate. Over 20 or more cycles, those small failures add up, creating a mix of unwanted molecules right alongside the target peptide. That's why the purity figure on a certificate of analysis (COA) matters. In a vial labeled 95% pure, about 5% of the detected material is something other than the target sequence.

A 2014 review of impurities in peptide medicines describes the main synthesis-related types. The table below summarizes the ones most relevant to research peptides.

Users sometimes describe swelling at the injection site or a flu-like "peptide flu" that they blame on impurities. That's plausible in some cases, but we couldn't find a study that traced these reports to a specific impurity, and similar symptoms show up in user reports for the peptides themselves. Endotoxin is a better-established culprit. It's a fragment of bacterial cell walls that gets in through non-sterile handling rather than through the chemistry, and it can cause fever and inflammatory reactions after injection. Our page on monitoring protocols for peptide use covers which blood tests users report and what trials measured.

Purification: HPLC and Lyophilization

After synthesis, a reputable lab's job is only half done. The next step is purification, most often by high-performance liquid chromatography (HPLC). The raw peptide mixture is forced under high pressure through a column packed with material that separates molecules based on their chemical properties. The target peptide travels at a different speed than most truncated and deletion sequences.

The lab collects only the fraction that contains the target peptide. Impurities that behave almost identically, such as some diastereomers, are harder to separate. The purity figure on a COA is usually a direct readout from an HPLC run. It shows a large peak for the target peptide and, ideally, only very small bumps for any remaining impurities. A messy chart with lots of different peaks points to a poor synthesis or purification. HPLC purity doesn't confirm identity, though. That takes mass spectrometry, which checks that the main peak has the expected molecular weight. Our guide to peptide sourcing and quality control covers how to read a COA and how third-party testing works.

Once purified, the peptide is in a liquid solution and needs to be made stable for shipping and storage. This is done through lyophilization, or freeze-drying. The purified peptide solution is frozen and then placed under a vacuum, which causes the frozen water to turn directly into a gas, leaving a dry, stable powder. Freezing and drying are stresses in their own right, so drug manufacturers design the drying cycle carefully and often add stabilizers. A properly lyophilized peptide is usually a fluffy, uniform 'puck' at the bottom of the vial. A poorly lyophilized one might look smeared or melted, which can mean heat damage, though appearance alone can't show whether the peptide inside has degraded.

What Independent Testing Has Found

A cheap peptide may be cheap because the manufacturer cut corners on synthesis reagents or didn't run the purification long enough. That may be one reason one person has a good experience with BPC-157 and another gets nothing but red, itchy injection sites. They may not have been using the same compound, even if the label was identical. Expectation effects and differences in dose likely explain part of that gap too.

As of October 2026, the largest analysis of gray-market vials is an April 2026 preprint (not yet peer-reviewed) covering 6,441 samples of 14 peptides from a public third-party testing dataset. Depending on whether compounding-pharmacy or drug-manufacturing standards were applied, 41.6% to 71.1% of samples failed on purity, measured amount or identity, and 156 samples didn't contain the stated peptide at all. Of the 243 samples tested for endotoxin, 15% had quantifiable levels. Endotoxin didn't track HPLC purity, so a high purity figure doesn't rule out bacterial contamination.

The dataset has limits. Consumers and vendors chose which samples to submit, so it isn't a random sample of the market, and the authors note that poor batches may be underrepresented. Fewer than 4% of samples were tested for endotoxin. Even so, the findings fit what the chemistry predicts: each stage of synthesis and purification leaves room for error, and a label can't show what a specific vial contains. Some users pay for independent testing of their own vials. Others get blood work during a cycle, though routine blood tests won't identify a specific impurity.